I
01541
ImmuneOnco Biopharmaceuticals (S…
3.150
+0.240+8.25%Closed16:08 08/07 HKT
OPEN/PREV CLOSE3.090/3.155
TODAY RANGE3.090-3.625
VOL1.52M
MARKET CAP1.54B
52 WEEK RANGE2.800-16.800
AVG VOL (3M)1.23M
% TURNOVER0.35%
TURNOVER5.33M
P/E (TTM)-6.327
% RANGE16.96%
EPS(TTM)-0.564
P/E(FORWARD)-11.994
P/B1.747
BVPS2.040
DIVIDEND--
P/S8.964
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.49B
SHARES OUTSTANDING431.51M
NEXT EARNINGS08/24-08/31
FREE FLOAT418.46M
LOT SIZE200
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·06/08 04:05
Asian Market Insights: ImmuneOnco Biopharmaceuticals (Shanghai) Among 3 Promising Penny Stocks
Simply Wall St·03/27 13:16
ImmuneOnco Biopharmaceuticals (SEHK:1541) Losses Narrow 23.6% Annually Challenging Bearish Narratives
Simply Wall St·01/07 01:08
While institutions invested in ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) benefited from last week's 10% gain, individual investors stood to gain the most
Simply Wall St·08/28/2025 22:52
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) 9.3% loss last week hit both individual investors who own 46% as well as institutions
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.